Sandostatin is a brand name of octreotide, approved by the FDA in the following formulation(s):
SANDOSTATIN (octreotide acetate - injectable; injection)
Manufacturer: NOVARTIS
Approval date: October 21, 1988
Strength(s): EQ 0.05MG BASE/ML [RLD][AP], EQ 0.1MG BASE/ML [RLD][AP], EQ 0.5MG BASE/ML [RLD][AP]
Manufacturer: NOVARTIS
Approval date: June 12, 1991
Strength(s): EQ 0.2MG BASE/ML [RLD][AP], EQ 1MG BASE/ML [RLD][AP]
Has a generic version of Sandostatin been approved?
A generic version of Sandostatin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Sandostatin and have been approved by the FDA:
octreotide acetate injectable; injection
Manufacturer: APP PHARMS
Approval date: February 10, 2006
Strength(s): EQ 0.2MG BASE/ML [AP], EQ 1MG BASE/ML [AP]
Manufacturer: SUN PHARM INDS
Approval date: August 14, 2007
Strength(s): EQ 0.05MG BASE/ML [AP], EQ 0.1MG BASE/ML [AP], EQ 0.2MG BASE/ML [AP], EQ 0.5MG BASE/ML [AP], EQ 1MG BASE/ML [AP]
Manufacturer: SUN PHARM INDS
Approval date: March 4, 2008
Strength(s): EQ 0.05MG BASE/ML [AP], EQ 0.1MG BASE/ML [AP], EQ 0.2MG BASE/ML [AP], EQ 0.5MG BASE/ML [AP], EQ 1MG BASE/ML [AP]
Manufacturer: TEVA PARENTERAL
Approval date: October 3, 2005
Strength(s): EQ 0.05MG BASE/ML [AP], EQ 0.1MG BASE/ML [AP], EQ 0.5MG BASE/ML [AP]
Manufacturer: TEVA PARENTERAL
Approval date: November 21, 2005
Strength(s): EQ 0.2MG BASE/ML [AP], EQ 1MG BASE/ML [AP]
Manufacturer: WOCKHARDT USA
Approval date: May 11, 2011
Strength(s): EQ 0.2MG BASE/ML [AP], EQ 1MG BASE/ML [AP]
OCTREOTIDE ACETATE (PRESERVATIVE FREE) (octreotide acetate injectable; injection)
Manufacturer: APP PHARMS
Approval date: February 10, 2006
Strength(s): EQ 0.05MG BASE/ML [AP], EQ 0.1MG BASE/ML [AP], EQ 0.5MG BASE/ML [AP]
Manufacturer: MYLAN INSTITUTIONAL
Approval date: February 10, 2011
Strength(s): EQ 0.05MG BASE/ML [AP], EQ 0.1MG BASE/ML [AP], EQ 0.5MG BASE/ML [AP]
Manufacturer: WOCKHARDT USA
Approval date: May 11, 2011
Strength(s): EQ 0.05MG BASE/ML [AP], EQ 0.1MG BASE/ML [AP], EQ 0.5MG BASE/ML [AP]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sandostatin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Somatostatin analogue composition and use in treating breast cancer
Patent 5,753,618
Issued: May 19, 1998
Inventor(s): Cavanak; Thomas & Harris; Alan
Assignee(s): Novartis Corporation
The invention provides a pharmaceutical composition containing a somatostatin analogue, and its use in the treatment of breast cancer. The pharmaceutical composition preferably contains lactic acid in addition to the somatostatin analogue and is better tolerated when administered by injection.Patent expiration dates:
- May 19, 2015
- November 19, 2015✓
- May 19, 2015
See also...
- Sandostatin Consumer Information (Drugs.com)
- Sandostatin Consumer Information (Wolters Kluwer)
- Sandostatin injectable Consumer Information (Cerner Multum)
- Sandostatin Advanced Consumer Information (Micromedex)
- Octreotide Consumer Information (Wolters Kluwer)
- Octreotide Kit Consumer Information (Wolters Kluwer)
- Octreotide injectable Consumer Information (Cerner Multum)
- Octreotide Injection, Intramuscular Advanced Consumer Information (Micromedex)
- Octreotide Acetate AHFS DI Monographs (ASHP)
No comments:
Post a Comment